Scotia Capital Inc. Cuts Stock Position in BioNTech SE Sponsored ADR $BNTX

Scotia Capital Inc. trimmed its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 77.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,081 shares of the company’s stock after selling 85,000 shares during the period. Scotia Capital Inc.’s holdings in BioNTech were worth $2,670,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Banque Cantonale Vaudoise bought a new stake in BioNTech during the 1st quarter valued at approximately $36,000. LRI Investments LLC grew its holdings in BioNTech by 234.6% during the 2nd quarter. LRI Investments LLC now owns 445 shares of the company’s stock valued at $47,000 after buying an additional 312 shares in the last quarter. Hantz Financial Services Inc. raised its position in shares of BioNTech by 472.0% during the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock valued at $61,000 after buying an additional 472 shares during the last quarter. Banque Transatlantique SA purchased a new position in shares of BioNTech in the first quarter worth $80,000. Finally, Costello Asset Management INC purchased a new position in shares of BioNTech in the first quarter worth $91,000. Institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

BNTX has been the subject of several research analyst reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a research note on Wednesday, November 12th. UBS Group raised their price objective on BioNTech from $115.00 to $117.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a report on Tuesday, October 14th. Bank of America decreased their target price on BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a research report on Wednesday, October 22nd. Finally, HC Wainwright raised their price target on BioNTech from $136.00 to $140.00 and gave the company a “buy” rating in a report on Monday, November 10th. Ten investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $135.20.

BioNTech Stock Down 1.4%

Shares of NASDAQ:BNTX opened at $101.26 on Monday. The firm has a market capitalization of $22.80 billion, a PE ratio of -63.29 and a beta of 1.54. The business has a 50 day simple moving average of $103.06 and a two-hundred day simple moving average of $105.20. BioNTech SE Sponsored ADR has a 1 year low of $81.20 and a 1 year high of $129.27. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The business had revenue of $1.78 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the prior year, the business posted $0.81 earnings per share. BioNTech’s revenue was up 22.0% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. On average, equities analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.